EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study

Wei-Hsiang Tseng, Cheng-Hsien Lin, Yu-Chen Su, Ling-Chiao Teng, Chieh-Lin Jerry Teng iD

Journal of International Medical Research · 2026-06 · 54 (6)

DOI: 10.1177/03000605261456028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of International Medical Research, online erschienen am 12.06.2026. Verfasst von Wei-Hsiang Tseng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan. Hauptthemen laut MEDLINE: Valganciclovir, Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Cytomegalovirus. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taichung Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cytomegalovirus reactivation is a clinically significant complication after allogeneic hematopoietic stem cell transplantation. Valganciclovir is commonly used for cytomegalovirus prophylaxis; however, the optimal dosing strategy remains unclear. This study compared the efficacy and safety of ultra-low-dose valganciclovir (450 mg every other day) and low-dose valganciclovir (450 mg daily) in preventing cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

Methods

We retrospectively reviewed adult patients who underwent allogeneic hematopoietic stem cell transplantation from January 2020 to December 2023. Individuals receiving low-dose (n = 31) or ultra-low-dose (n = 35) valganciclovir as cytomegalovirus prophylaxis were included. Cytomegalovirus DNAemia was evaluated within the first 14 weeks and then at 14–28 weeks after transplantation. Cytomegalovirus disease, acute graft-versus-host disease, survival outcomes, and hematologic toxicities were also assessed.

Results

The prevalence of early cytomegalovirus reactivation was 13.8% in the low-dose group and 20.0% in the ultra-low-dose group ( p = 0.301). Late reactivation rates were similarly low in the low-dose and ultra-low-dose groups (3.6% vs. 6.2%, p = 1.000). Hematologic adverse events were comparable; however, treatment discontinuation due to cytopenia was significantly more common with low-dose therapy (48.4% vs. 17.1%, p = 0.007). Overall survival (80.6% vs. 75.8%, p = 0.839) and acute graft-versus-host disease (29.1% vs. 45.7%, p = 0.381) rates did not exhibit statistically significant differences between the two groups.

Conclusions

Ultra-low-dose valganciclovir demonstrated better tolerability but may provide less protection against cytomegalovirus reactivation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValganciclovirCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationCytomegalovirusAntiviral AgentsHumansRetrospective StudiesFemaleAdultMiddle AgedMaleTransplantation, HomologousVirus ActivationGraft vs Host DiseaseDose-Response Relationship, Drug

Stichwörter der Autor:innen

Cytomegalovirusdosehematopoietic stem cell transplantationvalganciclovir

Substanzen

ValganciclovirAntiviral Agents

Autor:innen und Institutionen

  • Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan.
  • Department of Nursing, Taichung Veterans General Hospital, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taiwan.
  • Department of Life Science, Tunghai University, Taiwan.
  • Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taiwan.

ORCID-Profile: Chieh-Lin Jerry Teng

Förderung

  • Taichung Veterans General Hospital

Zitieren

APA

Tseng, W. H., Lin, C. H., Su, Y. C., Teng, L. C., & Teng, C. J. (2026). Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study. Journal of International Medical Research, 54(6). https://doi.org/10.1177/03000605261456028

Vancouver

Tseng WH, Lin CH, Su YC, Teng LC, Teng CJ. Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study. Journal of International Medical Research. 2026;54(6). doi:10.1177/03000605261456028

BibTeX
@article{Tseng2026,
  author = {Tseng, Wei-Hsiang and Lin, Cheng-Hsien and Su, Yu-Chen and Teng, Ling-Chiao and Teng, Chieh-Lin Jerry},
  title = {Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study},
  journal = {Journal of International Medical Research},
  year = {2026},
  volume = {54},
  number = {6},
  doi = {10.1177/03000605261456028}
}
Kostenlos starten →